These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21461654)

  • 1. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
    Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
    Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
    [No Abstract]   [Full Text] [Related]  

  • 6. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
    Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
    Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
    Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
    Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
    Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 15. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
    Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Jun; 14(2):150-4. PubMed ID: 21327443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
    Okubo K; Arigami T; Matsushita D; Tanaka T; Tsuruda Y; Noda M; Sasaki K; Mori S; Kurahara H; Ohtsuka T
    Oncology; 2021; 99(6):380-388. PubMed ID: 33677434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2331-3. PubMed ID: 22202372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
    Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
    Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.